A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
Robert A Scott, Daniel F Freitag, Li Li, Audrey Y Chu, Praveen Surendran, Robin Young, Niels Grarup, Alena Stancáková, Yuning Chen, Tibor V Varga, Hanieh Yaghootkar, Jian'an Luan, Jing Hua Zhao, Sara M Willems, Jennifer Wessel, Shuai Wang, Nisa Maruthur, Kyriaki Michailidou, Ailith Pirie, Sven J van der Lee
- The National Institute of Environmental Health Sciences
- Brigham and Women's Hospital
- University Hospital of Kuopio
- Lund University
- University of Cambridge
- Indiana University-Purdue University Indianapolis
- Johns Hopkins University
- Erasmus University Medical Center
- Université Lille 1
- CIBER Epidemiologia y Salud Pública (CIBERESP)
- University of Strasbourg
- University Paris Sud 11
- University of Washington, Seattle
- University Hospital Hamburg-Eppendorf
- University of Michigan
- German Institute of Human Nutrition
- Baylor College of Medicine
- University of Birmingham
- NHLBI's Framingham Heart Study
- Washington University in St. Louis
- Uppsala University Hospital
- Istituto di Ricerca Genetica eBiomedica
- University of Copenhagen, Denmark
- Harvard University
- University of Exeter
- University of London
- University of Glasgow
- University Hospitals Coventry and Warwickshire NHS Trust
106
Link opens in a new tab
Citations
(Scopus)